Sichuan Kelun-Biotech Biopharma has become the first drugmaker to usher a TROP2-targeted antibody-drug conjugate to ...

The partners are pushing to expand Enhertu’s list of indications beyond its standing uses in breast, lung and gastric cancers ...

AstraZeneca and Daiichi Sankyo have claimed ... cleared TROP2-directed ADC datopotamab deruxtecan (Dato-DXd) under the Datroway trade name as a treatment for previously treated HR+/HER2- breast ...

The pharmaceutical industry is evolving continuously with the advancements in drug discovery with Artificial Intelligence (AI), propelling the industry’s growth. Amid this backdrop, quality medical ...

In January this year, AstraZeneca and partner Daiichi’s drug, Datroway/datopotamab deruxtecan was approved by the FDA for HR+ HER2- breast cancer while a regulatory application is under review ...

AstraZeneca secured approvals for two new molecular entities. Kavigale received EU approval for the prevention of COVID-19 in immunocompromised people aged 12 years and older. Datroway was ...

Datroway shows promising antitumor activity in advanced NSCLC with EGFR mutations and ALK rearrangements, achieving a 35.8% overall response rate. The treatment maintains a manageable safety profile, ...